A 1-year-old boy received a living-related liver transplantation (LRLT) from his HLA-haploidentical father to treat acute liver failure following non-A, non-B, non-C hepatitis. He subsequently developed pancytopenia and was diagnosed with aplastic anemia (AA). He was platelet transfusion dependent and developed two episodes of life-threatening intracranial hemorrhage despite immuno-suppressive therapy consisting of cyclosporin A, antithymocyte globulin, and anabolic steroids. He received combined hematopoietic stem cell transplantation (hSCT) with cord blood and bone marrow from an HLA-matched sibling. Conditioning consisted of cyclophosphamide (CY) 200 mg/kg and 7 Gy total lymphoid irradiation (TLI). Marrow engraftment was prompt and there was no significant graft-versus-host disease (GVHD).
Some cases of hepatitis-associated aplastic anemia respond to immuno-suppressive therapy, such as cyclosporin A (CsA) and antithymocyte globulin (ATG), even after LT. [1] [2] [3] Many other non-responders, however, have died of infection or hemorrhage due to bone marrow failure. [1] [2] [3] Recent case reports have demonstrated the feasibility of allogeneic bone marrow transplantaion in cases of aplastic anemia following LT from a cadaveric donor for non-A, non-B, non-C hepatitis, which resulted in prompt marrow engraftment without any sign of severe graft-versus-host disease (GVHD) or veno-occlusive disease (VOD) of the liver. [4] [5] [6] [7] Correspondence: K Umeda, Department of Pediatrics, Graduate School of Medicine, Kyoto University, 54 Kawahara- We report successful combined hSCT with cord blood and bone marrow in a boy with aplastic anemia after LRLT for fulminant non-A, non-B, non-C hepatitis.
Case report
A 1-year-old boy was transferred to our hospital for treatment of acute liver failure, with markedly elevated bilirubin and transaminase levels (sGOT 2183 IU/l, sGPT 2041 IU/l, total birulubin 8.9 mg/dl) in May 1996. On admission, he had marked jaundice and grade III encephalopathy. The total bilirubin had increased to 11.0 mg/dl with a direct bilirubin of 5.0 mg/dl, and the sGOT and sGPT had decreased to 68 IU/l and 51 IU/l. CBC levels did not show any obvious changes and the prothrombin time was 17.0 s (control 11.8 s). Serologies for hepatitis A, B, and C as well as CMV and EBV were all negative. His blood type was A(Ϫ) and HLA typing was as follows; HLA-A: 24/-, -B: 39/52, -C: 4/6, -DR: 15/8.
He immediately received a LT from his HLA-haploidentical father. The donor was CMV-seropositive, blood type O(+), and HLA-A: 2/24, -B: 39/52, -DR: 15/8. The patient received tacrolimus (FK506) and prednisolone for prophylaxis of graft rejection. Although his clinical symptoms and signs attributable to fulminant liver failure rapidly improved without any complications including graft rejection, thrombocytopenia was noted 4 months after LRLT. Thereafter, he progressed to pancytopenia (WBC, 1.8 ϫ 10 9 /l; neutrophil count, 0.6 ϫ 10 9 /l ; Plt, 19 ϫ 10 9 /l; Hb, 8.8 g/dl, reticulocytes, 3.2‰), and was diagnosed with hepatitisτassociated aplastic anemia based on bone marrow biopsy in November 1996, without any evidence of malignancy or chromosomal abnormalities. Fanconi anemia was excluded by the absence of spontaneous or mitomycin Cinduced chromosomal breakage.
Immuno-suppressive therapies (IST) consisting of cyclosporin A (CsA), horse antithymocyte globulin (ATG), and anabolic steroids were started, but only partial hematological recovery occurred (neutrophil count Ͼ1.0 ϫ 10 9 /l); the thrombocytopenia did not improve and he remained dependent on platelet transfusions and developed two episodes of life-threatening intracranial hemorrhage.
An HLA serologically matched, ABO-incompatible (donor B(Ϫ) to recipient A(Ϫ)) sister was born and the cord blood (CB) was cryopreserved in February 1999. The total mononuclear cells of her CB were about 2.0 ϫ 10 7 cells/kg body weight; we decided not to transplant until her bone marrow (BM) could be safely harvested for combination with the CB, for fear of a higher risk of graft rejection due to multiple-transfusion-associated sensitization with minor histocompatibility antigens from the donor.
On readmission for hSCT, physical examination was normal. Laboratory investigations were as follows: WBC, 2.5 ϫ 10 9 /l; neutrophils, 0.8 ϫ10 9 /l ; plt, 37 ϫ 10 9 /l; Hb, 8.2 g/dl, reticulocytes, 4.3‰; sGOT, 35 IU/ml; sGPT, 15 IU/ml; LDH, 302 IU/ml; fasting blood glucose, 72 mg/dl; total bilirubin 0.4 mg/dl, respectively. The patient was asymptomatic, but both CMV-pp65 antigen and EBV-DNA were detected in peripheral blood leukocytes just before hSCT. Although cardiac ultrasonography (US) and chest X-ray were normal, abdominal US indicated narrowing of the hepatic veins and reduction in flow.
The clinical course of hSCT is shown in Figure 1 . The patient received conditioning with Cy, 50 mg/kg/day from day Ϫ5 to day Ϫ2, and 7 Gy of TLI on day Ϫ1. For GVHD prophylaxis, he received CsA 3 mg/kg/day as a continuous infusion from day Ϫ1, methotrexate 15 mg/m 2 i.v. on day 1, and 10 mg/m 2 on days 3 and 5. He also received ursodeoxycolic acid, low molecular weight heparin, antithrombin III (AT-III), and prostaglandin E 1 for VOD prophylaxis. For prophylaxis and treatment of viral infections, he received gancyclovir (GCV) 5 mg/kg/day i.v. twice a day from day Ϫ14 to day Ϫ1, which was restarted at 5 mg/kg/day i.v. from day 12, acyclovir (ACV) 5 mg/kg/day i.v. from day Ϫ21 to day 35, combined with high-titer immunoglobulins at 250 mg/kg i.v. for EBV and CMV twice a week from day Ϫ14. Granulocyte colony-stimulating factor (G-CSF) was started from day 6 to engraftment.
In April 2001, the patient was given a transfusion of 1.35 ϫ 10 8 BM cells/kg body weight (after processing using a CS-3000 plus cell separator for depletion of red blood cells) and 2.12 ϫ 10 7 cryopreserved CB cells/kg body weight from his sister. Neither CMV nor EBV was detected in his peripheral blood at day Ϫ1. Hematological engraftment was quite prompt; the time for absolute neutrophil counts to reach more than 0.5 ϫ 10 9 /l was day 12, reticulocytes more than 10‰ day 14, Plt more than 50 ϫ 10 9 /l day 45; full chimerism was confirmed by XY FISH on BM on day 23. Microchimerism derived from LT donor lymphocytes was not detected by polymerase chain reaction (PCR) analysis of short tandem repeats in BM either before or after the combined transplant.
On day 18, the patient developed a persistent fever which was unresponsive to broad spectrum antibiotics; this subsided quickly following administration of amphotericin B and G-CSF as a continuous infusion. There was no acute GVHD or recurrence of CMV and EBV.
The patient complained of right upper quadrant pain from day 23, and physical examination showed marked hepatomegaly of 8 cm without any symptoms related to VOD, such as jaundice or weight gain. He sequentially developed thrombocytopenia which remained unresponsive to platelet transfusions, and which was diagnosed as VOD on liver biopsy on day 27, demonstrating congestion and fibrous stenosis of the central veins. His symptoms improved on treatment with high-dose AT-III consisting of 50 units/kg/day three times per day for 3 days, and thereafter, 50 units/kg/day once per day for 6 days.
He was alive and free from disease 9 months after the combined hSCT with no signs of liver dysfunction or chronic GVHD.
Discussion
Recent studies have shown that many patients receiving LT for fulminant hepatitis related to non-A, non-B, non-C hepatitis subsequently develop aplastic anemia. [1] [2] [3] The fact that some cases respond to IST, such as CsA and ATG strengthens the hypothesis that hepatitis-associated aplastic anemia is in part mediated by immunopathologic mechanisms. [1] [2] [3] Because the outcomes of almost all cases which 533 Table 1 Hematopoietic stem cell transplantations in aplastic anemia following orthotopic liver transplantation for non-A, non-B, non-C hepatitis hSCT = hematopoietic stem cell transplantation; LT = liver transplantation; VOD = veno-occlusive disease of liver; Cy = cyclophosphamide; ATG = antithymocyte globulin; CsA = cyclosporin A; MTX = methotrexate; PDN = prednisolone; CMV = cytomegalovirus; EBV = Epstein-Barr virus; EFS = event-free survival; TLI = total lymphoid irradiation; HSV = herpes simple virus.
did not respond to IST have been dismal, hSCT is recommended for the treatment of such non-responders as early as possible, especially if they have an HLAτmatched related donor. As shown in Table 1 , there have been four cases reported as receiving SCT for aplastic anemia following LT for fulminant hepatitis. [4] [5] [6] [7] In all cases the hSCT donors were HLAτmatched siblings. In contrast, all LT donors have been cadavers except for our case. This first successful report of hSCT after LRLT is encouraging, considering that almost all LTs have been performed from living related donors in Japan.
Severe acute GVHD of the liver was not observed in any of these cases. It has been suggested by both experimental and clinical studies that LT can provide better allograft acceptance than other solid organ transplants, and that donor-derived leukocytes, especially antigen-presenting cells working in the context of MHC, play a major role in the immunotolerance of the allograft by inducing anergy or apoptosis of recipient T cells. 8 These cells may induce immunotolerance of the allograft by a similar mechanism when the subsequent hSCT is performed from an HLAmatched donor, although LT donor-derived leukocytes could not be detected in our case.
Recurrent viral infections such as CMV and EBV are often serious complications after LTs and are due to longterm administration of immuno-suppressive agents for prophylaxis of graft rejection. CMV is the main cause of severe interstitial pneumonia or retinitis after hSCT, but the frequency of severe CMV infections has recently decreased; firstly, due to effective anti-viral agents such as GCV or foscarnet, and secondly, due to early detection using pp65 antigen or PCR analysis. In contrast, EBV frequently gives rise to fatal post-transplant lymphoproliferative disease (PTLD), and anti-viral agents are usually ineffective against it. Fortunately, none of these five cases developed severe infection after hSCT, despite the high rate of CMV and EBV viremia before hSCT. Furthermore, adoptive immunotherapy such as infusion of donor lymphocytes 9 and viral-specific cytotoxic T cells or CD20 mono-
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clonal antibody (rituximab) 10 can be an effective treatment for fulminant EBV infections after hSCT.
VOD is known to be a major complication after hSCT. Several risk factors for VOD have been identified, including pretransplant factors such as age, disease status, number of transplants, and liver status just before hSCT. In this case, VOD developed despite vigorous prophylaxis even though it was mild enough to be curable. Anastomotic stricture of the hepatic veins should be considered as one of the most crucial risk factors for developing VOD.
In conclusion, we were able to successfully perform hSCT for the treatment of aplastic anemia after LT for fulminant non-A, non-B, non-C hepatitis. Although no definite conclusions can be drawn from the small number of cases with relatively short periods of follow-up, hSCT after LT may provide an equivalent cure rate to conventional hSCT if a recipient in good physical condition is selected who can provide adequate stem cells.
